Champignon Provides Corporate Update; Announces Name Change, Rebranding and Planned Spin Out Post published:June 12, 2020 Post category:Press Release
Champignon Announces Closing of $15 Million Bought Deal Private Placement Post published:June 11, 2020 Post category:Press Release
Champignon Identifies Synthetic Ketamine and Psilocybin/Psilicin Metabolite Targets; Selects Dalriada to Advance NCE IP Portfolio Post published:June 8, 2020 Post category:Press Release
Champignon Announces Voluntary Share Lock-Up; Retains Gold Standard Media, LLC for Financial Marketing Services Post published:May 29, 2020 Post category:Press Release
Champignon Appoints Dr. Bill Wilkerson, Executive Chairman of Mental Health International to Board of Directors Post published:May 25, 2020 Post category:Press Release
Champignon Sponsors Non-profit Coalition, TheraPsil – Medical Psilocybin Access Project for Palliative Cancer Patients and Health Professionals Post published:May 18, 2020 Post category:Press Release
Interview with Dr. Roger McIntyre, CEO of Champignon Brands Post published:May 14, 2020 Post category:Interview
Champignon Expands to U.S., To Acquire California Based Ketamine Centre – Wellness Clinic of Orange County Post published:May 12, 2020 Post category:Press Release